Talk:VALIANT

Automated review 2019-02-14T06:14:06

• Article marked as usable but bot founds error. See entry in Articles in Review.

== Since baseline characteristics were very similar across all three groups I didn't include them. However, here they are in case anyone deems them important enough to include (numbers are obviously post-randomization)

• Mean age:
  • Valsartan: 65.0 years
  • Valsartan & captopril: 64.6 years
  • Captopril: 64.9 years
• Race in percent: White (w); Black (b); Asian (a); Other (o)
  • Valsartan: w=93.8; b=2.5; a= 0.8; o= 2.8
  • Valsartan & captopril: w=93.2; b=2.8; a=1.1; o=2.9
  • Captopril: w=93.5; b=3.0; a=0.9; o=2.6
• Female gender (%):
  • Valsartan: 1544 (31.5)
  • Valsartan & captopril: 1490 (30.5)
  • Captopril: 1536 (31.3)
• Median BMI:
  • Valsartan: 27.34
  • Valsartan & captopril: 27.24
  • Captopril: 27.14
• Left ventricular ejection fraction (all three groups) = 35.3
• Killip class in percent:
  • Class I
    • Valsartan: 26.5
    • Valsartan & captopril: 28.4
    • Captopril: 29.1
  • Class II
    • Valsartan: 49.2
    • Valsartan & captopril: 47.9
    • Captopril: 48.0
  • Class III
    • Valsartan: 17.9
    • Valsartan & captopril: 17.3
    • Captopril: 16.6
  • Class IV
    • Valsartan: 6.4
    • Valsartan & captopril: 6.4
    • Captopril: 6.3